Dataset Information

Brain CB? Receptors: Implications for Neuropsychiatric Disorders.

ABSTRACT: Although previously thought of as the peripheral cannabinoid receptor, it is now accepted that the CB? receptor is expressed in the central nervous system on microglia, astrocytes and subpopulations of neurons. Expression of the CB? receptor in the brain is significantly lower than that of the CB? receptor. Conflicting findings have been reported on the neurological effects of pharmacological agents targeting the CB? receptor under normal conditions. Under inflammatory conditions, CB? receptor expression in the brain is enhanced and CB2 receptor agonists exhibit potent anti-inflammatory effects. These findings have prompted research into the CB? receptor as a possible target for the treatment of neuroinflammatory and neurodegenerative disorders. Neuroinflammatory alterations are also associated with neuropsychiatric disorders and polymorphisms in the CB? gene have been reported in depression, eating disorders and schizophrenia. This review will examine the evidence to date for a role of brain CB? receptors in neuropsychiatric disorders.

SUBMITTER: Roche M

PROVIDER: S-EPMC4033937 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.

Roche Michelle M Finn David P DP

Pharmaceuticals (Basel, Switzerland) 20100810 8

Although previously thought of as the peripheral cannabinoid receptor, it is now accepted that the CB₂ receptor is expressed in the central nervous system on microglia, astrocytes and subpopulations of neurons. Expression of the CB₂ receptor in the brain is significantly lower than that of the CB₁ receptor. Conflicting findings have been reported on the neurological effects of pharmacological agents targeting the CB₂ receptor under normal conditions. Under inflammatory conditions, CB₂ receptor e ...[more]

PMID: 27713365

Similar Datasets

Project description:Melatonin, the primary indoleamine hormone of the mammalian pineal gland, is known to have a plethora of neuroregulatory, neuroprotective and other properties. Melatonergic signalling is mediated by its two GPCRs, MT1 and MT2 , which are widely expressed in the mammalian CNS. Melatonin levels and receptor expression often show a decrease during normal ageing, and this reduction may be accelerated in some disease states. Depleted melatonergic signalling has been associated with neuropsychiatric dysfunction and impairments in cognition, memory, neurogenesis and neurorestorative processes. The anticonvulsant and mood stabilizer, valproic acid (VPA), up-regulates melatonin MT1 and/or MT2 receptor expression in cultured cells and in the rat brain. VPA is known to affect gene expression through several mechanisms, including the modulation of intracellular kinase pathways and transcription factors, as well as the inhibition of histone deacetylase (HDAC) activity. Interestingly, other HDAC inhibitors, such as trichostatin A, which are structurally distinct from VPA, can also up-regulate melatonin receptor expression, unlike a VPA analogue, valpromide, which lacks HDAC inhibitory activity. Moreover, VPA increases histone H3 acetylation along the length of the MT1 gene promoter in rat C6 cells. These findings indicate that an epigenetic mechanism, linked to histone hyperacetylation/chromatin remodelling and associated changes in gene transcription, is involved in the up-regulation of melatonin receptors by VPA. Epigenetic induction of MT1 and/or MT2 receptor expression, in areas where these receptors are lost because of ageing, injury or disease, may be a promising therapeutic avenue for the management of CNS dysfunction and other disorders. LINKED ARTICLES: This article is part of a themed section on Recent Developments in Research of Melatonin and its Potential Therapeutic Applications. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc.

Dataset Information

Brain CB? Receptors: Implications for Neuropsychiatric Disorders.

Publications

Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure